News | August 25, 2022
Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim
The cash consideration for the above acquisition will be Euro 26 million.
The cash consideration for the above acquisition will be Euro 26 million.
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
Company appoints five new independent directors to reconstituted board
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
